Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Natureยท2026
Same author

Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.

Leukemiaยท2026
Same author

Insomnia in Breast Cancer: A Neglected Symptom Cluster.

Journal of clinical medicineยท2026
Same author

Reprogramming of TLR-Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer.

Cancer researchยท2026
Same author

Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study.

Breast (Edinburgh, Scotland)ยท2026
Same author

Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study.

NPJ breast cancerยท2026

Related Experiment Video

Updated: Apr 12, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.1K

Widespread renal polycystosis induced by crizotinib.

Marco Di Girolamo1, Ida Paris, Francesco Carbonetti

  • 1Department of Radiology, Sapienza University of Rome, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Rome - Italy.

Tumori
|May 9, 2015
PubMed
Summary

Crizotinib, a targeted therapy for non-small-cell lung cancer, can cause aggressive kidney polycystic disease. This condition resolved after discontinuing crizotinib treatment, offering insights for managing this rare side effect.

More Related Videos

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

10.3K
Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease
12:47

Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease

Published on: February 3, 2012

39.5K

Related Experiment Videos

Last Updated: Apr 12, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.1K
Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

10.3K
Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease
12:47

Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease

Published on: February 3, 2012

39.5K

Area of Science:

  • Oncology
  • Pharmacology
  • Nephrology

Background:

  • Chemotherapy landscape is evolving with targeted therapies like crizotinib.
  • Crizotinib is an anaplastic lymphoma kinase (ALK) and ROS1 inhibitor used in advanced non-small-cell lung carcinoma.
  • Understanding drug-induced side effects is crucial for effective patient management.

Observation:

  • A case of diffuse and aggressive renal polycystosis was observed.
  • This condition was induced by crizotinib treatment.
  • The polycystic kidney disease showed significant regression after crizotinib cessation.

Findings:

  • Crizotinib can induce severe renal polycystic disease.
  • The observed renal polycystosis regressed upon discontinuation of crizotinib.
  • This case highlights a rare but significant adverse effect of crizotinib.

Implications:

  • Physicians should be aware of the potential for crizotinib-induced renal polycystosis.
  • Monitoring kidney function in patients treated with crizotinib is recommended.
  • Management strategies may involve dose adjustment or drug cessation, leading to disease regression.